Combination treatments may be the future for treating patients with spinal muscular atrophy (SMA) at all stages and ages, explained Jill Jarecki, PhD, chief scientific officer at Cure SMA and research director of TREAT-NMD Neuromuscular Network.
Combination treatments may be the future for treating patients with spinal muscular atrophy (SMA) at all stages and ages, explained Jill Jarecki, PhD, chief scientific officer at Cure SMA and research director of TREAT-NMD Neuromuscular Network.
Transcript
What else is in the pipeline for SMA and how do those therapies differ from what is already approved?
So, at CureSMA, we're working to fund a number of drugs in the SMA drug pipeline and the reason for that is that there has been dramatic changes with the FDA approved drugs in our presymptomatic in our younger patient population. And we also get clinically meaningful, but more modest gains, in our older patients who are chronically living with SMA.
So, we believe that we need a cocktail approach to achieve maximally effective benefit in all stages and ages of SMA. And this likely means combination therapies, and combination therapies that target either muscle function or motor neuron function. Muscle drugs are the furthest along with this sort of combination, or cocktail, approach. And we have a drug in clinical trials with Scholar Rock that helps with the muscle side of things.
And in our pipeline, we have many early stage drugs that focus on more diverse approaches, and that's where CureSMA is currently directing our funding, to help identify novel drug approaches for SMA that can be layered on with our approved SMN [survival of the motor neuron] upregulating drugs.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More